Lonza Says It Is on Track to Deliver Guidance
By Billy Gray
Lonza Group said its third-quarter performance was strong, with a return to growth at its capsules-and-health ingredients unit, and that it is on track to achieve full-year guidance for its core contract drug manufacturing business.
The Swiss company on Thursday reiterated full-year expectations and said both its contract development and manufacturing organization and capsules and health ingredients businesses were on track to deliver better sales results in the second half of 2025 than in the first.
The company didn't provide specific numbers for the third quarter.
Lonza said its capsules and health ingredients business returned to growth and continued its strong U.S. manufacturing presence.
The group said it expected a robust level of contract signing across technologies and sites, including at its large-scale biopharmaceuticals site in California.
It said in July that it expected its contract-drug-manufacturing sales to grow by between 20% and 21% excluding currency movements for the full year, with a core earnings before interest, taxes, depreciation and amortization margin of 30% to 31%.
Write to Billy Gray at william.gray@wsj.com
(END) Dow Jones Newswires
October 23, 2025 01:51 ET (05:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States